BREAST CANCER--SPECIFIC CELLULAR IMMUNITY AND BEHAVIOR

乳腺癌——特异性细胞免疫和行为

• 批准号: 3549101
• 负责人: MAURICE M BLACK
• 金额: $ 45.72万
• 依托单位: NEW YORK MEDICAL COLLEGE
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-08-01 至 1991-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3549101
• 关键词: breast neoplasm /cancer diagnosis; breast neoplasms; cancer registry /resource; cancer risk; cytodiagnosis; female; host neoplasm interaction; human subject; metastasis; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; prognosis

The long-term objective of the proposed study is to reduce the risk of breast cancer (BCa) by immunizing control women against a cell-mediated immunity (CMI) determinant of preinvasive BCa. The immediate objectives are: a) correlating the risk of metastases with the degree of nuclear differentiation (nuclear grade, NG) of the primary BCa and skin window (SW) reactivity against autologous BCa tissue, b) correlating the risk of second primary BCa with SW reactivity against the first BCa and/or the gp55 component of the RIII-murine mammary tumor virus. These objectives are derived from prior observations by the Principal Investigator and associates on the prognostic significance of prospectively classified NG and SW reactivity: 1. NG is inversely correlated with the risk of early metastases from BCa; 2. SW reactivity against NG-characterized autologous BCa in inversely correlated with the risk of early metastases; 3. SW reactivity against autologous BCa is inversely correlated with the risk of a second invasive BCa within the subsequent four years; 4. the prognostically significant immunogen of BCa is characterized by a CMI determinant which is similar to one of gp 55; 5. this gp55-like CMI determinant is characteristically expressed during the preinvasive phase of mammary carcinogenesis; thus, SW reactivity to gp55 is inversely correlated with the risk of an invasive BCa within the subsequent four years. The proposed prospective study will determine whether these findings can be reproduced under the following conditions: 1. participation of BCa patients from different geographic areas; 2. morphologic classification of all primary BCa under coded conditions; 3. tests of SW reactivity against autologous BCa and gp55 at defined postoperative intervals, performed by different teams; 4. evaluation of SW test results under coded conditions; 5. collation and statistical evaluation of all data by a central registry at the NCI. Confirmation of the significance of the correlation of NG and SW reactivity with subsequent behavior of BCa would be important with regard to a) individualization of current therapy and b) development of immunoprophylaxis.

拟议研究的长远目标是减少 乳腺癌的风险（BCa）通过免疫控制妇女， 侵袭前BCa的细胞介导免疫（CMI）决定因素。 直接目标是：a）将 转移与核分化程度（核 原发性BCa和皮肤窗（SW）反应性 B）将第二次BCa组织的风险与第二次BCa组织的风险相关联， 具有针对第一BCa的SW反应性的原发BCa和/或 RIII-鼠乳腺肿瘤病毒的gp55组分。 这些 目标来自于委托人先前的观察结果 研究者和同事对预后的意义， 前瞻性分类NG和SW反应性：1. NG是反向的 与BCa早期转移的风险相关; 2. SW 与NG特征性自体BCa的反应性呈反比， 与早期转移的风险相关; 3. SW反应性 与自体BCa的风险呈负相关 在随后的四年内第二次侵入性BCa; 4. 的 BCa的免疫学显著性免疫原的特征在于： CMI决定簇，其类似于gp 55之一; 5.这种类似gp55的 CMI决定簇的特征性表达是在 乳腺癌发生的浸润前阶段;因此，SW反应性 gp55与侵袭性BCa的风险呈负相关 在接下来的四年里。 拟议的前瞻性研究将确定这些 研究结果可在以下条件下重现：1. 来自不同地理区域的BCa患者的参与; 2. 所有编码下的原发性BCa的形态分类 条件; 3. SW对自体BCa的反应性试验， gp55在规定的术后间隔，由不同的 团队; 4.编码条件下软件测试结果的评价; 5. 由一个中央机构对所有数据进行整理和统计评价， 在NCI注册。 确认NG和SW相关性的意义 与BCa后续行为的反应性将是重要的 关于a）当前治疗的个体化和B） 免疫预防的发展。